Potentials as biomarker and therapeutic target of upregulated long non-coding RNA HLA-F antisense RNA 1 in hepatitis B virus-associated hepatocellular carcinoma.

Autor: Zhang X; Department of Gastroenterology, First Affiliated Hospital of Jiamusi University, Jiamusi, 154002, Heilongjiang, China., Li W; Department of Gastroenterology, First Affiliated Hospital of Jiamusi University, Jiamusi, 154002, Heilongjiang, China., Li S; Department of Gastroenterology, First Affiliated Hospital of Jiamusi University, Jiamusi, 154002, Heilongjiang, China., Zhang Z; Department of Gastroenterology, First Affiliated Hospital of Jiamusi University, Jiamusi, 154002, Heilongjiang, China., Song W; School of Basic Medicine, Jiamusi University, No. 258, Xuefu Street, Xiangyang District, Jiamusi, 154000, Heilongjiang, China. xuemeizhang@hrbmu.edu.cn.
Jazyk: angličtina
Zdroj: Virus genes [Virus Genes] 2024 Jun; Vol. 60 (3), pp. 243-250. Date of Electronic Publication: 2024 Apr 03.
DOI: 10.1007/s11262-024-02065-8
Abstrakt: The tissue-specific characteristics have encouraged researchers to identify organ-specific lncRNAs as disease biomarkers. This study aimed to identify the clinical and functional roles of long non-coding RNA HLA-F antisense RNA 1 (HLA-F-AS1) in hepatitis B virus (HBV)-hepatocellular carcinoma (HCC). A total of 121 HBV-HCC, 81 chronic hepatitis B (CHB), and 85 normal liver tissues were evaluated in this study. Real-time quantitative PCR assay was used to evaluate the RNA expression levels. Performance in diagnosis was compared between alpha fetoprotein (AFP) and HLA-F-AS1 using Receiver Operating Characteristic (ROC) curves. Performance in post-hepatectomy prognosis with high or low HLA-F-AS1 was compared using Kaplan-Meier curves. Multi-variable analysis was used to determine the informative predictors. Downstream miRNAs for HLA-F-AS1 were predicted and miR-128-3p was confirmed by luciferase reporter assay and RNA pull-down assay. In vitro functional analysis was performed by MTS reagent for cell proliferation and transwell assay for cell migration. HLA-F-AS1 levels were significantly increased in the HBV-HCC compared to normal healthy tissue and CHB tissues. HLA-F-AS1 exhibited a well potential in making a distinction between HBV-HCC and health, as well as HBV-HCC and CHB. The survival analysis revealed that patients with high levels of HLA-F-AS1 tend to shorter overall survival times. The best prognostic performance was achieved by HLA-F-AS1 after multi-variable analysis (HR 2.290, 95% CI 1.191-4.403, p = 0.013). Functional analysis showed that HLA-F-AS1 promoted cell proliferation and migration via miR-128-3p. Up-regulation of HLA-F-AS1 could serve as a promising diagnostic and prognostic marker for HBV-HCC after surgery, maybe useful in the management of HBV-HCC patients. HLA-F-AS1 can promote the progression of HBV-HCC, may be useful in the targeting treatment of HBV-HCC patients.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: